Although it has yet to be ratified by Congress, there appears to be a clear path forward to approval of the U.S.-Mexico-Canada Agreement (USMCA) for trade among the three North American countries. Among the updates in the revised agreement are a few that affect the pharma industry: the removal of a 10-year exculsivity provision for biologic drugs, opening the way for biosimilar competition, and provisions to encourage competition among drug companies to reduce prices. This is a mixed bag for pharma companies, but it will open the way to more clinical trials for generic/biosimilar products for existing biologic drugs, a boon to patients and to companies invested in biosimilar development. With our global network and extensive temperature-controlled packaging and premium courier capabilities, Yourway is positioned to support companies investigating biosimilars in clinical trials.